Literature DB >> 31386174

National risk prediction model for perioperative mortality in non-cardiac surgery.

D Campbell1, L Boyle2, M Soakell-Ho3, P Hider4, L Wilson5, J Koea6, A F Merry1,7, C Frampton8, T G Short1,7.   

Abstract

BACKGROUND: Many multivariable models to calculate mortality risk after surgery are limited by insufficient sample size at development or by application to cohorts distinct from derivation populations. The aims of this study were to validate the Surgical Outcome Risk Tool (SORT) for a New Zealand population and to develop an extended NZRISK model to calculate 1-month, 1-year and 2-year mortality after non-cardiac surgery.
METHODS: Data from the New Zealand National Minimum Data Set for patients having surgery between January 2013 and December 2014 were used to validate SORT. A random 75 per cent split of the data was used to develop the NZRISK model, which was validated in the other 25 per cent of the data set.
RESULTS: External validation of SORT in the 360 140 patients who underwent surgery in the study period showed good discrimination (area under the receiver operating characteristic curve (AUROC) value of 0·906) but poor calibration (McFadden's pseudo-R2 0·137, calibration slope 5·32), indicating it was invalid in this national surgical population. Internal validation of the NZRISK model, which incorporates sex and ethnicity in addition to the variables used in SORT for 1-month, 1-year and 2-year outcomes, demonstrated excellent discrimination with AUROC values of 0·921, 0·904 and 0·895 respectively, and excellent calibration (McFadden's pseudo-R2 0·275, 0·308 and 0·312 respectively). Calibration slopes were 1·12, 1·02 and 1·02 respectively.
CONCLUSION: The SORT performed poorly in this national population. However, inclusion of sex and ethnicity in the NZRISK model improved performance. Calculation of mortality risk beyond 30 days after surgery adds to the utility of this tool for shared decision-making.
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 31386174     DOI: 10.1002/bjs.11232

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Persistent opioid use and opioid-related harm after hospital admissions for surgery and trauma in New Zealand: a population-based cohort study.

Authors:  Jiayi Gong; Alan Forbes Merry; Kebede A Beyene; Doug Campbell; Chris Frampton; Peter Jones; John McCall; Matthew Moore; Amy Hai Yan Chan
Journal:  BMJ Open       Date:  2021-01-19       Impact factor: 2.692

2.  Acute Kidney Injury and 3-Year Mortality in Elderly Patients After Non-cardiac Surgery.

Authors:  Qiong-Fang Wu; Mao-Wei Xing; Wen-Jun Hu; Xian Su; Dan-Feng Zhang; Dong-Liang Mu; Dong-Xin Wang
Journal:  Front Med (Lausanne)       Date:  2022-04-12

3.  How to identify a high-risk surgical patient?

Authors:  André P Schmidt; Luciana C Stefani
Journal:  Braz J Anesthesiol       Date:  2022-04-21

4.  Regional variation in post-operative mortality in New Zealand.

Authors:  Jason K Gurney; Melissa McLeod; James Stanley; Bridget Robson; Douglas Campbell; Elizabeth Dennett; Dick Ongley; Juliet Rumball-Smith; Diana Sarfati; Jonathan Koea
Journal:  ANZ J Surg       Date:  2022-04-20       Impact factor: 2.025

5.  Postoperative mortality in New Zealand following general anaesthetic: demographic patterns and temporal trends.

Authors:  Jason K Gurney; Melissa McLeod; James Stanley; Doug Campbell; Luke Boyle; Elizabeth Dennett; Sarah Jackson; Jonathan Koea; Dick Ongley; Diana Sarfati
Journal:  BMJ Open       Date:  2020-09-24       Impact factor: 2.692

6.  Derivation and validation of a national multicenter mortality risk stratification model - the ExCare model: a study protocol.

Authors:  Sávio Cavalcante Passos; Adriene Stahlschmidt; João Blanco; Mariana Lunardi Spader; Rodrigo Borges Brandão; Stela Maris de Jezus Castro; Claudia de Souza Gutierrez; Paulo Corrêa da Silva Neto; Luciana Paula Cadore Stefani
Journal:  Braz J Anesthesiol       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.